Cytokines and NO-Synthases, Laboratory of Cellular and Molecular Biology (LBCM), Faculty of Biological Science, USTHB, PB 32, 16111, Algiers, Algeria.
Department of Nephrology, Dr Md Seghir NEKKACHE Hospital, Algiers, Algeria.
Inflammopharmacology. 2019 Dec;27(6):1113-1122. doi: 10.1007/s10787-019-00567-8. Epub 2019 Feb 5.
Behçet disease (BD) is a chronic multisystem disease. It stands at the crossroads between the auto-immunity and auto-inflammatory disorders. Our study aims to evaluate corticosteroids therapy effects on serum immunoglobulin isotypes and anti-phospholipid auto-anti-body production in Algerian BD patients with different clinical manifestations.
We evaluated serum immunoglobulin isotypes and anti-phospholipid (anti-cardiolipin, anti-β2glycoprotein I, anti-prothrombin) auto-anti-body production using Turbidimetric or Luminex platform assays. Our study was conducted in naïve active BD patients and in corticosteroid-treated patients with different clinical manifestations.
Our results indicate that IgM, IgG, and IgA levels were higher in naïve active patients. The increase in sera isotypes did not differ according to the clinical manifestation, except for IgA production, which was associated with an increased risk of mucocutaneous and ocular involvement. Interestingly, in corticosteroid-treated active patients, no difference was reported between each clinical subgroup. Furthermore,anti-cardiolipin, anti-β2glycoprotein I and anti-prothrombin auto-anti-body levels were elevated in naïve active patients. Contrary to anti-prothrombin, high anti-cardiolipin and anti-β2glycoprotein I, production differed according to the clinical manifestations and was associated with an increased risk of mucocutaneous and ocular involvement. Importantly, corticosteroid therapy significantly reduced these immune markers regardless of the clinical manifestations.
Our results suggest that high IgA production could be a risk marker of uveitis in naïve active patients. Moreover, concomitant high anti-cardiolipin, anti-β2glycoprotein I and anti-prothrombin production is related to an increased risk of mucocutaneous lesions, ocular and vascular involvement. Collectively, our data indicate the importance of evaluating the corticosteroid effect on immune responses associated with BD to ensure an adequate investigation of each related clinical manifestation.
贝赫切特病（BD）是一种慢性多系统疾病。它处于自身免疫和自身炎症性疾病之间的十字路口。我们的研究旨在评估不同临床表现的阿尔及利亚 BD 患者皮质类固醇治疗对血清免疫球蛋白同种型和抗磷脂自身抗体产生的影响。
我们使用比浊法或 Luminex 平台检测评估血清免疫球蛋白同种型和抗磷脂（抗心磷脂、抗-β2糖蛋白 I、抗凝血酶原）自身抗体的产生。我们的研究在初治活动期 BD 患者和不同临床表现的皮质类固醇治疗患者中进行。
我们的结果表明，初治活动期患者的 IgM、IgG 和 IgA 水平较高。血清同种型的增加与临床表现无关，除了 IgA 产生与黏膜皮肤和眼部受累的风险增加有关。有趣的是，在皮质类固醇治疗的活动期患者中，每个临床亚组之间均未报告差异。此外，初治活动期患者的抗心磷脂、抗-β2糖蛋白 I 和抗凝血酶原自身抗体水平升高。与抗凝血酶原相反，高抗心磷脂和抗-β2糖蛋白 I 的产生与临床表现不同，并与黏膜皮肤和眼部受累的风险增加有关。重要的是，皮质类固醇治疗显著降低了这些免疫标志物，无论临床表现如何。
我们的结果表明，高 IgA 产生可能是初治活动期患者葡萄膜炎的风险标志物。此外，同时存在高抗心磷脂、抗-β2 糖蛋白 I 和抗凝血酶原的产生与黏膜皮肤损伤、眼部和血管受累的风险增加有关。总之，我们的数据表明，评估与 BD 相关的皮质类固醇对免疫反应的影响非常重要，以确保对每个相关临床表现进行充分的调查。
